Cargando…
Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis
OBJECTIVES: To describe the point prevalence and clinical course of proteinuria in dogs diagnosed with idiopathic non‐erosive immune‐mediated polyarthritis. MATERIALS AND METHODS: Cases presenting to a single referral centre with a diagnosis of idiopathic non‐erosive immune‐mediated polyarthritis we...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542946/ https://www.ncbi.nlm.nih.gov/pubmed/35508589 http://dx.doi.org/10.1111/jsap.13503 |
_version_ | 1784804262683869184 |
---|---|
author | Barker, L. McManus, S. Adamantos, S. Black, V. |
author_facet | Barker, L. McManus, S. Adamantos, S. Black, V. |
author_sort | Barker, L. |
collection | PubMed |
description | OBJECTIVES: To describe the point prevalence and clinical course of proteinuria in dogs diagnosed with idiopathic non‐erosive immune‐mediated polyarthritis. MATERIALS AND METHODS: Cases presenting to a single referral centre with a diagnosis of idiopathic non‐erosive immune‐mediated polyarthritis were retrospectively recruited from January 2009 to August 2018. Data including signalment, urinalysis, clinicopathological results, cytology from arthrocentesis, treatment and long‐term follow‐up were analysed. Dogs were defined as: non‐proteinuric (UPC <0.2), borderline proteinuric (UPC 0.2‐0.5) or overtly proteinuric (UPC >0.5). RESULTS: Fifty‐eight dogs met the inclusion criteria. Twenty‐two dogs were overtly proteinuric (38%), eight dogs were borderline proteinuric (14%) and 28 dogs were non‐proteinuric (48%). Repeated urinalysis was performed in nine of 12 dogs with UPC greater than 2.0. The UPC decreased in all nine dogs, with the UPC decreasing to less than 0.5 in 44% of dogs. A greater than 50% decrease in UPC was noted in 44% of dogs, despite seven of nine (77%) receiving prednisolone as either monotherapy or in conjunction with an adjunctive immunosuppressive medication. CLINICAL SIGNIFICANCE: Proteinuria was common in this cohort of dogs diagnosed with primary idiopathic non‐erosive immune‐mediated polyarthritis. The use of prednisolone does not appear to be contraindicated in proteinuric dogs with idiopathic non‐erosive immune‐mediated polyarthritis. |
format | Online Article Text |
id | pubmed-9542946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-95429462022-10-14 Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis Barker, L. McManus, S. Adamantos, S. Black, V. J Small Anim Pract Original Articles OBJECTIVES: To describe the point prevalence and clinical course of proteinuria in dogs diagnosed with idiopathic non‐erosive immune‐mediated polyarthritis. MATERIALS AND METHODS: Cases presenting to a single referral centre with a diagnosis of idiopathic non‐erosive immune‐mediated polyarthritis were retrospectively recruited from January 2009 to August 2018. Data including signalment, urinalysis, clinicopathological results, cytology from arthrocentesis, treatment and long‐term follow‐up were analysed. Dogs were defined as: non‐proteinuric (UPC <0.2), borderline proteinuric (UPC 0.2‐0.5) or overtly proteinuric (UPC >0.5). RESULTS: Fifty‐eight dogs met the inclusion criteria. Twenty‐two dogs were overtly proteinuric (38%), eight dogs were borderline proteinuric (14%) and 28 dogs were non‐proteinuric (48%). Repeated urinalysis was performed in nine of 12 dogs with UPC greater than 2.0. The UPC decreased in all nine dogs, with the UPC decreasing to less than 0.5 in 44% of dogs. A greater than 50% decrease in UPC was noted in 44% of dogs, despite seven of nine (77%) receiving prednisolone as either monotherapy or in conjunction with an adjunctive immunosuppressive medication. CLINICAL SIGNIFICANCE: Proteinuria was common in this cohort of dogs diagnosed with primary idiopathic non‐erosive immune‐mediated polyarthritis. The use of prednisolone does not appear to be contraindicated in proteinuric dogs with idiopathic non‐erosive immune‐mediated polyarthritis. Blackwell Publishing Ltd 2022-05-04 2022-08 /pmc/articles/PMC9542946/ /pubmed/35508589 http://dx.doi.org/10.1111/jsap.13503 Text en © 2022 The Authors. Journal of Small Animal Practice published by John Wiley & Sons Ltd on behalf of British Small Animal Veterinary Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Barker, L. McManus, S. Adamantos, S. Black, V. Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis |
title | Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis |
title_full | Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis |
title_fullStr | Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis |
title_full_unstemmed | Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis |
title_short | Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis |
title_sort | point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542946/ https://www.ncbi.nlm.nih.gov/pubmed/35508589 http://dx.doi.org/10.1111/jsap.13503 |
work_keys_str_mv | AT barkerl pointprevalenceandclinicalcourseofproteinuriaindogswithidiopathicnonerosiveimmunemediatedpolyarthritis AT mcmanuss pointprevalenceandclinicalcourseofproteinuriaindogswithidiopathicnonerosiveimmunemediatedpolyarthritis AT adamantoss pointprevalenceandclinicalcourseofproteinuriaindogswithidiopathicnonerosiveimmunemediatedpolyarthritis AT blackv pointprevalenceandclinicalcourseofproteinuriaindogswithidiopathicnonerosiveimmunemediatedpolyarthritis |